铂敏感复发性卵巢癌维持治疗的真实世界模式
基于美国Flatiron Health电子健康记录数据库的回顾性研究,纳入2011年1月至2019年7月诊断的卵巢癌患者,分析接受二线或三线铂类化疗后维持治疗的模式。222例符合条件的患者中,BRCA突变者63%接受PARP抑制剂、17%贝伐珠单抗、20%主动监测;BRCA野生型者40%接受PARP抑制剂、23%贝伐珠单抗、36%主动监测;
要点
- 真实世界中二线或三线铂类化疗后维持治疗越来越普遍,不受生物标志物状态影响
- BRCA突变患者中63%接受PARP抑制剂,野生型患者中40%接受PARP抑制剂
核心结论
- 在真实世界人群中,二线或三线铂类化疗后维持治疗正逐渐普及,且不依赖于生物标志物状态。
研究设计与样本
- 回顾性研究,使用美国全国性Flatiron Health电子健康记录去标识数据库,纳入2011年1月1日至2019年7月31日诊断的卵巢癌患者,要求接受二线或三线铂类化疗,最终222例符合条件。
主要发现
- 222例完成铂类化疗并接受主动监测或维持治疗的患者中,46例(20%)有BRCA突变,132例(59%)为BRCA野生型,47例(21%)状态未知。
- BRCA突变患者中63%接受PARP抑制剂,17%接受贝伐珠单抗,20%接受主动监测。
- BRCA野生型患者中40%接受PARP抑制剂,23%接受贝伐珠单抗,36%接受主动监测。
- 维持治疗在年轻和BRCA突变患者中更常见。
临床怎么用
- 真实世界数据显示PARP抑制剂在铂敏感复发性卵巢癌维持治疗中的应用持续增长,BRCA突变患者使用率更高。
- 临床决策时可参考真实世界中BRCA野生型患者仍有相当比例接受PARP抑制剂或贝伐珠单抗维持治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The clinical utility of maintenance therapy (MT) for patients with platinum-sensitive recurrent ovarian cancer has been validated in several clinical trials. We assessed "real-world" treatment patterns using an electronic health record (EHR) database. METHODS: A retrospective study of patients diagnosed with ovarian cancer between January 1, 2011 and July 31, 2019 was conducted using the US nationwide Flatiron Health (EHR)-derived de-identified database. Patients were included if they received second- or third-line (2 L or 3 L) platinum-based chemotherapy (PBCT). Information regarding biomarker status was obtained. RESULTS: 2292 patients with ovarian cancer received at least two lines of therapy. 222 patients completed PBCT on or after March 1, 2017 and had ≥2 months of active surveillance or received MT with poly(adenosine diphosphate-ribose) polymerase inhibitors (PARPi) or bevacizumab. 46 (20%) had BRCA mutations (BRCAm), 132 (59%) had a wildtype BRCA (BRCAwt) gene, and 47 (21%) were unknown. Of patients with BRCAm, 63% received a PARPi, 17% received bevacizumab, and 20% underwent active surveillance. Of patients with BRCAwt, 40% received a PARPi, 23% received bevacizumab, and 36% underwent active surveillance. MT was more common in those with younger age and a BRCA mutation. PARPi use increased on average by 1.3% every 3 months (p = .02) with no statistically significant change in use of bevacizumab. CONCLUSIONS: In this real-world population, MT is becoming progressively more common following 2 L or 3 L PBCT regardless of biomarker status. The results provide insight into the shifting treatment patterns for patients with recurrent ovarian cancer.
引用
- Moss HA, Perhanidis JA, Havrilesky LJ, et al. Real-world treatment patterns of maintenance therapy in platinum-sensitive recurrent ovarian cancer. Gynecol Oncol. 2021. PMID: 34301411. doi:10.1016/j.ygyno.2021.07.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。